Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Raises Price Target to $37

Benzinga · 05/09 14:33
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and raises the price target from $36 to $37.